Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New Insight Into the Biology, Risk Stratification, and Targeted Treatment of Myelodysplastic Syndromes.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting - 1 Jan 2017

Haider Mintallah, Duncavage Eric J, Afaneh Khalid F, Bejar Rafael, List Alan F

Abstract excerpt

In myelodysplastic syndromes (MDS), somatic mutations occur in five major categories: RNA splicing, DNA methylation, activated cell signaling, myeloid transcription factors, and chromatin modifiers. Although many MDS cases harbor more than one somatic mutation, in general, there is mutual exclusivity of mutated genes within a class. In addition to the prognostic significance of individual somatic mutations, more...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Chromatin Assembly and Disassembly

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Methylation

Share to Molecular Targeted Therapy

Share to Myelodysplastic Syndromes

Share to Prognosis

Share to RNA Splicing

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 28561687
DOI: 10.1200/EDBK_175397

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New Insight Into the Biology, Risk Stratification, and Targeted Treatment of Myelodysplastic Syndromes.PMID 28561687Read ↗

Myelodysplastic syndromes: recent advancements in risk stratification and unmet therapeutic challenges.Semantic proximity Read ↗

The genetics of myelodysplastic syndromes and the opportunities for tailored treatmentsSemantic proximity Read ↗

Myelodysplastic syndromes: Updates on Genomic Landscape, Molecular Subtypes, & Targeted Therapies.Semantic proximity Read ↗

The spectrum of genetic mutations in myelodysplastic syndrome: Should we update prognostication?Semantic proximity Read ↗

Updates in Risk Stratification in Myelodysplastic Syndromes.Semantic proximity Read ↗

The evolving field of prognostication and risk stratification in MDS: Recent developments and future directions.Semantic proximity Read ↗

Unraveling the molecular pathophysiology of myelodysplastic syndromes.Semantic proximity Read ↗

Molecular pathophysiology of myelodysplastic syndromes.Semantic proximity Read ↗

New strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practice.Semantic proximity Read ↗

Current state of prognostication and risk stratification in myelodysplastic syndromes.Semantic proximity Read ↗

Recent advances in myelodysplastic syndromes: Molecular pathogenesis and its implications for targeted therapies.Semantic proximity Read ↗

Clinical and genetic predictors of prognosis in myelodysplastic syndromesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.